Effects of different HA and NA gene combinations on the growth characteristics of the H3N8 influenza candidate vaccine virus

IF 2.7 Q3 IMMUNOLOGY Vaccine: X Pub Date : 2024-08-01 DOI:10.1016/j.jvacx.2024.100531
Liqi Liu, Zi Li, Jia Liu, Xiyan Li, Jianfang Zhou, Ning Xiao, Lei Yang, Dayan Wang
{"title":"Effects of different HA and NA gene combinations on the growth characteristics of the H3N8 influenza candidate vaccine virus","authors":"Liqi Liu,&nbsp;Zi Li,&nbsp;Jia Liu,&nbsp;Xiyan Li,&nbsp;Jianfang Zhou,&nbsp;Ning Xiao,&nbsp;Lei Yang,&nbsp;Dayan Wang","doi":"10.1016/j.jvacx.2024.100531","DOIUrl":null,"url":null,"abstract":"<div><p>Since 2022, three human cases of a novel H3N8 avian influenza virus infection have been reported in three provinces in China. Specific vaccines are important means of preparing for the potential influenza pandemic. Thus, H3N8 viruses [A/Henan/cnic410/2022 (HN410) and A/Changsha/1000/2022(CS1000)] were isolated from the infected patients as prototype viruses to develop candidate vaccine viruses (CVVs) using the reverse genetics (RG) technology. Five reassortant viruses with different HA and NA combinations were constructed based on the two viruses to get a high-yield and safe CVV. The results showed that all viruses had similar antigenicity but different growth characteristics. Reassortant viruses carrying NA from CS1000 exhibited better growth ability and NA enzyme activity than the ones carrying HN410 NA. Furthermore, the NA gene of CS1000 had one more potential N-glycosylation site at position 46 compared with HN410. The substitution of position 46 showed that adding or removing N-glycosylation sites to different reassortant viruses had different effects on growth ability. A reassortant virus carrying HN410 HA and CS1000 NA with high growth ability was selected as a CVV, which met the requirements for a CVV. These data suggest that different surface gene combinations and the presence or absence of potential N-glycosylation sites on position 46 in the NA gene affect the growth characteristics of H3N8 CVVs.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"19 ","pages":"Article 100531"},"PeriodicalIF":2.7000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001049/pdfft?md5=f7cdf2466fc67d18eea671a1e35c55b6&pid=1-s2.0-S2590136224001049-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine: X","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590136224001049","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Since 2022, three human cases of a novel H3N8 avian influenza virus infection have been reported in three provinces in China. Specific vaccines are important means of preparing for the potential influenza pandemic. Thus, H3N8 viruses [A/Henan/cnic410/2022 (HN410) and A/Changsha/1000/2022(CS1000)] were isolated from the infected patients as prototype viruses to develop candidate vaccine viruses (CVVs) using the reverse genetics (RG) technology. Five reassortant viruses with different HA and NA combinations were constructed based on the two viruses to get a high-yield and safe CVV. The results showed that all viruses had similar antigenicity but different growth characteristics. Reassortant viruses carrying NA from CS1000 exhibited better growth ability and NA enzyme activity than the ones carrying HN410 NA. Furthermore, the NA gene of CS1000 had one more potential N-glycosylation site at position 46 compared with HN410. The substitution of position 46 showed that adding or removing N-glycosylation sites to different reassortant viruses had different effects on growth ability. A reassortant virus carrying HN410 HA and CS1000 NA with high growth ability was selected as a CVV, which met the requirements for a CVV. These data suggest that different surface gene combinations and the presence or absence of potential N-glycosylation sites on position 46 in the NA gene affect the growth characteristics of H3N8 CVVs.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
不同 HA 和 NA 基因组合对 H3N8 流感候选疫苗病毒生长特性的影响
自 2022 年以来,中国三个省份报告了三例人感染新型 H3N8 禽流感病毒的病例。特异性疫苗是应对潜在流感大流行的重要手段。因此,我们从感染者身上分离出 H3N8 病毒 [A/河南/cnic410/2022(HN410)和 A/长沙/1000/2022(CS1000)],作为利用反向遗传学(RG)技术开发候选疫苗病毒(CVV)的原型病毒。以这两种病毒为基础,构建了5种不同HA和NA组合的变种病毒,以获得高产、安全的候选疫苗病毒。结果表明,所有病毒的抗原性相似,但生长特性不同。与携带 HN410 NA 的病毒相比,携带 CS1000 NA 的后裔病毒具有更好的生长能力和 NA 酶活性。此外,与 HN410 相比,CS1000 的 NA 基因在第 46 位多了一个潜在的 N-糖基化位点。第 46 位的替换表明,在不同的变种病毒中添加或去除 N-糖基化位点对其生长能力有不同的影响。一种携带 HN410 HA 和 CS1000 NA、生长能力强的重交病毒被选为 CVV,符合 CVV 的要求。这些数据表明,不同的表面基因组合以及 NA 基因第 46 位潜在 N-糖基化位点的存在与否会影响 H3N8 CVV 的生长特性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Vaccine: X
Vaccine: X Multiple-
CiteScore
2.80
自引率
2.60%
发文量
102
审稿时长
13 weeks
期刊最新文献
Immunogenicities of vaccines including the immunoglobulin M-degrading enzyme of Streptococcus suis, rIdeSsuis, and protective efficacy against serotype 14 in piglets The importance of quality of health campaign information for outcome evaluation. A case study from Guinea-Bissau and Bangladesh Mumps outbreak in Zimbabwe: The case for universal MMR vaccination in Africa The clinical and economic value of enhanced influenza vaccines for the elderly in Argentina Cost of the typhoid conjugate vaccine introduction through an integrated campaign and follow-on routine immunization in Malawi
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1